The Modafinil and Fatigue Trial
Name of the Trial
Phase III Randomized Study of Modafinil for Fatigue in Cancer Patients Receiving Chemotherapy (URCC-U2901). See the protocol summary.
Principal Investigator
Dr. Gary Morrow, University of Rochester Cancer Center.
|
Gary Morrow, Ph.D., Principal
Investigator
(Courtesy of ASCO, 2001) |
Why This Trial Is Important
Fatigue affects many people with cancer, especially those receiving treatment.
Fatigue is complex and has biological, psychological, and behavioral causes.
Research suggests that the drug modafinil, a stimulant, may be effective in relieving
fatigue. This study is testing the ability of modafinil to reduce fatigue in cancer patients
who are receiving chemotherapy. The study will also examine the relationship between
depression and fatigue in patients treated with modafinil.
“Fatigue related to cancer and to cancer treatment are important issues,
especially for patients,” said Dr. Lori Minasian, chief of the National Cancer
Institute’s Community Oncology and Prevention Trials Research Group.
“Modafinil is one of the more innovative means of treating fatigue, since it works on
the body’s central nervous system. With this trial, NCI-supported researchers are
pursuing a different approach in combating the fatigue that often accompanies treatment for
cancer.”
Contact Information
This trial is no longer accepting new patients. To locate other cancer supportive
care clinical trials, search the NCI's database
of clinical trials or call the NCI's Cancer Information
Service at 1-800-4-CANCER (1-800-422-6237). The call is toll-free and completely
confidential. |
